Don't Buy Xencor Before Checking Its Fundamentals!

By Blake Campbell • Wednesday, September 20 12:06 • Permanent Link

Xencor sank -2.5% today, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

Xencor has moved -24.0% over the last year, and the S&P 500 logged a change of 19.0%
XNCR has an average analyst rating of buy and is -53.31% away from its mean target price of $44.08 per share
Its trailing earnings per share (EPS) is $-2.11
Xencor has a trailing 12 month Price to Earnings (P/E) ratio of -9.8 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-2.54 and its forward P/E ratio is -8.1
The company has a Price to Book (P/B) ratio of 1.84 in contrast to the S&P 500's average ratio of 2.95
Xencor is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $-78855000, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.